bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

bioAffinity Technologies Announces Closing of Warrant Inducement Transaction for Aggregate Gross Proceeds of $1.4 Million

by Maria Zannes | Feb 26, 2025 | Press Releases

SAN ANTONIO, Texas (February 26, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has closed its previously announced warrant exercise agreements with four existing accredited investors to exercise certain outstanding warrants to...

bioAffinity Technologies Announces Warrant Inducement for Aggregate Gross Proceeds of $1.4 Million

by Maria Zannes | Feb 25, 2025 | Press Releases

SAN ANTONIO, Texas (February 25, 2024) – bioAffinity Technologies, Inc. (NASDAQ: BIAF and BIAFW) announced today it has entered into warrant exercise agreements with three existing accredited investors to exercise certain outstanding warrants to purchase an aggregate...

bioAffinity Technologies Announces Acceptance of Patent Application for Early-Stage Lung Cancer Diagnostic

by Maria Zannes | Jan 22, 2025 | Press Releases

SAN ANTONIO, Texas (Jan. 22, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage lung cancer and other lung diseases, today announced that the Australian...

bioAffinity Technologies Reports Positive Results from Texas Beta Launch of CyPath® Lung

by Maria Zannes | Jan 13, 2025 | Press Releases

SAN ANTONIO, TX (Jan. 13, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, today reported the results of the Company’s CyPath® Lung...

Join bioAffinity Technologies’ Exclusive Live Investor Webinar and Q&A Session on Thursday, December 19

by Maria Zannes | Dec 17, 2024 | Press Releases

SAN ANTONIO, TX (Dec. 17, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, invites investors to a webinar on Dec. 19, 2024, at 4:15 p.m. ET. The...

bioAffinity Technologies Set for Continued Expansion in 2025

by Maria Zannes | Dec 12, 2024 | Press Releases

Noninvasive CyPath® Lung test for lung cancer contributes to growing revenues  SAN ANTONIO, TX (Dec. 12, 2024) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage...
« Older Entries
Next Entries »

Categories

  • Articles (27)
  • Events (38)
  • News (52)
  • Press Releases (122)
  • Publications (17)

Recent Posts

  • bioAffinity Technologies Announces New U.S. Patent for Novel Broad Spectrum Cancer Therapeutics May 28, 2025
  • bioAffinity Technologies Appoints Dr. Gordon Downie, MD, PhD, as Chief Medical Officer May 20, 2025
  • bioAffinity Technologies Reports First Quarter 2025 Results May 15, 2025
  • Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer May 8, 2025
  • bioAffinity Technologies Announces Closing of $3.25 Million Offering May 7, 2025

Learn About CyPath Lung

CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.